Foley, J F, Defer, G, Ryerson, L Z, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Smirnakis, K, Xiao, S, Kong, G, NOVA study investigators, Kuhelj, R & Campbell, N 2022, ' Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial ', Lancet Neurology, vol. 21, no. 7, pp. 608-619 . https://doi.org/10.1016/S1474-4422(22)00143-0 The lancet neurology Lancet Neurology, 21(7), 608-619. Lancet Publishing Group
New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2020, 383 (6), pp.546-557. ⟨10.1056/NEJMoa1917246⟩ The New England journal of medicine New England Journal of Medicine, 2020, 383 (6), pp.546-557. ⟨10.1056/NEJMoa1917246⟩ The New England journal of medicine, Vol. 383, no. 6, p. 546-557 (2020)